We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA REORGANIZES CANCER DRUG DIVISIONS TO EXPEDITE REVIEW AND POLICY
FDA REORGANIZES CANCER DRUG DIVISIONS TO EXPEDITE REVIEW AND POLICY
July 23, 2004
The FDA plans to create an Office of Oncology Drug Products (ODP), as well as a new crosscutting oncology program, to get more cancer drugs on the market, according to an official at the agency’s Center for Drug Evaluation and Research (CDER).